Mundipharma
Tam Cilgi is an accomplished professional in regulatory strategy, currently serving as Senior Director, Global Regulatory Strategy and Labelling Lead at Mundipharma since March 2025. Prior experience includes roles as Director of Global Regulatory Strategy at Mallinckrodt Pharmaceuticals, Director of EUCAN Regulatory Strategy Lead at Pfizer, and Global Regulatory Lead at GE Healthcare. Tam Cilgi has also held positions such as Global Regulatory Strategy Manager at Indivior and Director, Project Head of Medicines and Drugs Regulation at International Development Ireland. Earlier career experience encompasses leadership in regulatory affairs at Chemilines and a scientific assessor role with the Medicines and Healthcare Products Regulatory Agency. Tam Cilgi holds a PhD and a Master's degree in Biological Sciences from the University of Southampton, along with post-doctoral research fellowship experience in the same field.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.